on October 24, 2005
Published online before print October 24, 2005, doi: 10.1161/CIRCULATIONAHA.105.535484
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on January 12, 2005
From the Department of Internal Medicine II, Cardiology, University of Ulm, Ulm, Germany. * To whom correspondence should be addressed. E-mail: wolfgang.koenig{at}medizin.uni-ulm.de.
Background--Restenosis requiring reintervention limits the long-term success after coronary stent implantation. Thiazolidinediones, like pioglitazone or rosiglitazone, are oral antidiabetic drugs with additional antirestenotic properties. In a randomized, placebo-controlled, double-blind trial, we examined the effect of 6-month pioglitazone therapy on neointima volume after coronary stenting in nondiabetic coronary artery disease patients. Methods and Results--Fifty nondiabetic patients after coronary stent implantation were randomly assigned to pioglitazone (30 mg daily; pio) or placebo (control) treatment in addition to standard therapy, and neointima volume was assessed by intravascular ultrasound at the 6-month follow-up. Both groups were comparable with regard to baseline characteristics, angiographic lesion morphology, target vessel, and length of the stented segment. In addition, there were no statistical differences in minimal lumen diameter before and after intervention, as well as reference diameter after stent implantation. In this study population of nondiabetic patients, pio treatment did not significantly change fasting blood glucose, fasting insulin, or glycosylated hemoglobin levels, as well as lipid parameters. In contrast, pio treatment significantly reduced neointima volume within the stented segment, with 2.3±1.1 mm3/mm in the pio group versus 3.1±1.6 mm3/mm in controls (P=0.04). Total plaque volume (adventitia-lumen area) was significantly lower at follow-up in the pio group (11.2±3.2 mm3/mm) compared with controls (13.2±4.2 mm3/mm; P=0.04). Moreover, the binary restenosis rate was 3.4% in the pio group versus 32.3% in controls (P<0.01). Conclusions--Thus, 6-month treatment with pio significantly reduced neointima volume after coronary stent implantation in nondiabetic patients. These data bolster the hypothesis that antidiabetic thiazolidinediones, in addition to their metabolic effects, exhibit direct antirestenotic effects in the vasculature.
Revised on June 6, 2005
Accepted on June 7, 2005
Pioglitazone Reduces Neointima Volume After Coronary Stent Implantation. A Randomized, Placebo-Controlled, Double-Blind Trial in Nondiabetic Patients
Nikolaus Marx MD,
Key words: stents • thiazolidinediones • intima • coronary disease • diabetes mellitus
Related Article:
Circulation 2005 112: 2753.
This article has been cited by other articles:
 |
|
 |
|
  J. M. Kleinhenz, D. J. Kleinhenz, S. You, J. D. Ritzenthaler, J. M. Hansen, D. R. Archer, R. L. Sutliff, and C. M. Hart Disruption of endothelial peroxisome proliferator-activated receptor-{gamma} reduces vascular nitric oxide production Am J Physiol Heart Circ Physiol, November 1, 2009; 297(5): H1647 - H1654. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Kaneda, T Shiono, Y Miyashita, S Takahashi, Y Taketani, H Domae, J Matsumi, S Mizuno, Y Minami, K Sugitatsu, et al. Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation Heart, July 1, 2009; 95(13): 1079 - 1084. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Takagi, H. Okura, Y. Kobayashi, T. Kataoka, H. Taguchi, I. Toda, K. Tamita, A. Yamamuro, Y. Sakanoue, A. Ito, et al. A Prospective, Multicenter, Randomized Trial to Assess Efficacy of Pioglitazone on In-Stent Neointimal Suppression in Type 2 Diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study) J. Am. Coll. Cardiol. Intv., June 1, 2009; 2(6): 524 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Mittal, S. Malhotra, P. Pandhi, I. Kaur, and S. Dogra Efficacy and Safety of Combination Acitretin and Pioglitazone Therapy in Patients With Moderate to Severe Chronic Plaque-Type Psoriasis: A Randomized, Double-blind, Placebo-Controlled Clinical Trial Arch Dermatol, April 1, 2009; 145(4): 387 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Q. Shen, A. Child, G. M. Weber, J. Folkman, and L. P. Aiello Rosiglitazone and Delayed Onset of Proliferative Diabetic Retinopathy Arch Ophthalmol, June 1, 2008; 126(6): 793 - 799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Steg and M. Marre Does PERISCOPE Provide a New Perspective on Diabetic Treatment? JAMA, April 2, 2008; 299(13): 1603 - 1604. [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Ohman, Y. Shen, C. I. Obimba, A. P. Wright, M. Warnock, D. A. Lawrence, and D. T. Eitzman Visceral Adipose Tissue Inflammation Accelerates Atherosclerosis in Apolipoprotein E-Deficient Mice Circulation, February 12, 2008; 117(6): 798 - 805. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. McGuire and S. E. Inzucchi New Drugs for the Treatment of Diabetes Mellitus: Part I: Thiazolidinediones and Their Evolving Cardiovascular Implications Circulation, January 22, 2008; 117(3): 440 - 449. [Full Text] [PDF]
|
|
|
|
 |
|
 C.-C. Fang, Yeun Tarl Fresner Ng Jao, Yi-Chen, C.-L. Yu, C.-L. Chen, and S.-P. Wang Angiographic and Clinical Outcomes of Rosiglitazone in Patients With Type 2 Diabetes Mellitus After Percutaneous Coronary Interventions: A Single Center Experience Angiology, November 1, 2007; 58(5): 523 - 534. [Abstract] [PDF]
|
|
|
|
 |
|
 A. S. Kelly, A. M. Thelen, D. R. Kaiser, J. M. Gonzalez-Campoy, and A. J. Bank Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus Vascular Medicine, November 1, 2007; 12(4): 311 - 318. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Werner, C. H. Kamani, C. Gensch, M. Bohm, and U. Laufs The Peroxisome Proliferator Activated Receptor-{gamma} Agonist Pioglitazone Increases Number and Function of Endothelial Progenitor Cells in Patients With Coronary Artery Disease and Normal Glucose Tolerance Diabetes, October 1, 2007; 56(10): 2609 - 2615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J Balmforth, P. J Grant, E. M Scott, S. B Wheatcroft, M. T Kearney, B. Staels, and N. Marx Inter-subject differences in constitutive expression levels of the clock gene in man Diabetes and Vascular Disease Research, March 1, 2007; 4(1): 39 - 43. [Abstract] [PDF]
|
|
|
|
|
|
J. D. Brown and J. Plutzky Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets Circulation, January 30, 2007; 115(4): 518 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Joner, A. Farb, Q. Cheng, A. V. Finn, E. Acampado, A. P. Burke, K. Skorija, W. Creighton, F. D. Kolodgie, H. K. Gold, et al. Pioglitazone Inhibits In-Stent Restenosis in Atherosclerotic Rabbits by Targeting Transforming Growth Factor-{beta} and MCP-1 Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 182 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A Ajjan and P. J Grant Cardiovascular disease prevention in patients with type 2 diabetes: the role of oral anti-diabetic agents Diabetes and Vascular Disease Research, December 1, 2006; 3(3): 147 - 158. [Abstract] [PDF]
|
|
|
|
 |
|
 J. J. Fuster and V. Andres Telomere Biology and Cardiovascular Disease Circ. Res., November 24, 2006; 99(11): 1167 - 1180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B Patle, J. A De Lemos, K. L Wyne, and D. K McGuire Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPAR{gamma} agonism Diabetes and Vascular Disease Research, September 1, 2006; 3(2): 65 - 71. [Abstract] [PDF]
|
|
|
|
 |
|
 Z. T. Bloomgarden Third Annual World Congress on the Insulin Resistance Syndrome: Atherothrombotic disease Diabetes Care, August 1, 2006; 29(8): 1973 - 1980. [Full Text] [PDF]
|
|
|
|
|
|
K. Hara, M. Horikoshi, T. Yamauchi, H. Yago, O. Miyazaki, H. Ebinuma, Y. Imai, R. Nagai, and T. Kadowaki Measurement of the High-Molecular Weight Form of Adiponectin in Plasma Is Useful for the Prediction of Insulin Resistance and Metabolic Syndrome. Diabetes Care, June 1, 2006; 29(6): 1357 - 1362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Dixon, C. L. Grines, and W. W. O'Neill The Year in Interventional Cardiology J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1689 - 1706. [Full Text] [PDF]
|
|
|
|
|
|
D. Ogawa, T. Nomiyama, T. Nakamachi, E. B. Heywood, J. F. Stone, J. P. Berger, R. E. Law, and D. Bruemmer Activation of Peroxisome Proliferator-Activated Receptor {gamma} Suppresses Telomerase Activity in Vascular Smooth Muscle Cells Circ. Res., April 14, 2006; 98(7): e50 - e59. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Meisner, D. Walcher, F. Gizard, X. Kapfer, R. Huber, A. Noak, L. Sunder-Plassmann, H. Bach, C. Haug, M. Bachem, et al. Effect of Rosiglitazone Treatment on Plaque Inflammation and Collagen Content in Nondiabetic Patients: Data From a Randomized Placebo-Controlled Trial Arterioscler Thromb Vasc Biol, April 1, 2006; 26(4): 845 - 850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schomig, A. Kastrati, and R. Wessely Prevention of Restenosis by Systemic Drug Therapy: Back to the Future? Circulation, November 1, 2005; 112(18): 2759 - 2761. [Full Text] [PDF]
|
|